ArticleCancer prevention research (Philadelphia, Pa.)2011
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
140 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Urinary biomarkers for the detection of ovarian cancer: a systematic review.Carcinogenesis · 2022Pooled it
- Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium.Journal of the National Cancer Institute · 2014Pooled it
- Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.British journal of cancer · 2019Trial
- Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Trial
- A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.British journal of cancer · 2017Trial
- Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.BioMed research international · 2015Trial
- Immunosignature system for diagnosis of cancer.Proceedings of the National Academy of Sciences of the United States of America · 2014Trial
- Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.Gynecologic oncology · 2012Trial
- Designing early detection programs for ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2011Trial
- Identification of macrophage-enriched genes in ovarian cancer by single-cell RNA sequencing and establishment of a prognosis model.Scientific reports · 2026Article
- Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study.Journal of ovarian research · 2026Article
- Somatic mutations in cervicovaginal samples: assessing their role in ovarian cancer detection and prognosis.Translational oncology · 2026Article
- Early Detection and Prevention of Ovarian Cancer.Cancers · 2025Review
- High-Throughput Peptide Array Clinical Validation for Lung Adenocarcinoma Detection.ACS omega · 2025Article
- Low transthyretin is associated with the poor prognosis of colorectal cancer.Frontiers in oncology · 2025Article
- Gynecological Insights into Lynch Syndrome-A Comprehensive Review of Cancer Screening and Prevention.Medicina (Kaunas, Lithuania) · 2024Review
- 5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.JCO precision oncology · 2024Article
- The Feasibility for Screening for Ovarian Cancer.EJIFCC · 2024Article
- Sensitivity and Specificity of Selected Biomarkers and Their Combinations in the Diagnosis of Ovarian Cancer.Diagnostics (Basel, Switzerland) · 2024Review
80 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
Establishing a cancer screening biomarker's intended performance requires "phase III" specimens obtained in asymptomatic individuals before clinical diagnosis rather than "phase II" specimens obtained from symptomatic individuals at diagnosis. We used specimens from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate ovarian cancer biomarkers previously assessed in phase II sets. Phase II specimens from 180 ovarian cancer cases and 660 benign disease or general population controls were assembled from four Early Detection Research Network or Ovarian Cancer Specialized Program of Research Excellence sites and used to rank 49 biomarkers. Thirty-five markers, including 6 additional markers from a fifth site, were then evaluated in PLCO proximate specimens from 118 women with ovarian cancer and 474 matched controls. Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40. Except for transthyretin, these markers had similar or better sensitivity when moving to phase III specimens that had been drawn within 6 months of the clinical diagnosis. Performance of all markers declined in phase III specimens more remote than 6 months from diagnosis. Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.